Founded in 2012 to simplify the complex U.S. healthcare system, $OSCR today serves 2M+ members, runs at $11.8B revenue, and holds ~$2.3B net cash.

The U.S. health insurance TAM exceeds $2.1T. If Oscar can grow its market share from ~1% → 3–4% over the next years, the upside is massive. It doesn’t need a “moonshot” to $620/share — just steady share gains and executing on its 2026 profitability plan.

At ~0.1x EV/Sales, the market values Oscar like a broken insurer. In reality, it’s a tech-first health platform with an AI edge (Superagent + GPT-5).

📌 My view: is a contrarian play with asymmetric upside. Big TAM, strong tech, dirt-cheap valuation.

$OSCR has improved its adjusted operating margin by +24 percentage points in 5 years

Still slightly negative (–1.2% TTM), but the trend is clear: strong revenue growth is driving operating leverage.

Profitability isn’t a dream anymore — it’s within reach. 💡

#stocks
#healthcare

$OSCR has grown revenues at a 72% CAGR over the last 5 years 🚀

That’s not a one-off quarter, that’s long-term momentum.

Oscar isn’t just another insurer — it’s building a healthtech growth story that customers clearly want.

#stocks
#healthcare
#growth

Fantastic YTD.

We are in ghe last months of bull market.

Follow the pump, follow $BTC (+0,11 %)
$ETH (+0,46 %)
$SOL (-0,94 %)
$AVAX (+0,1 %) like pump bull signal.

Be ready to trim your high beta stock.

$HIMS (-1,93 %)
$OSCR
$SOFI (-0,3 %)
$NBIS (+0 %)
$RKLB (+1,25 %)
$BABA (+2,63 %)
$BIDU (+9,1 %)
$UNH (-0,27 %)
$DLO
$TMDX (+1,52 %)
$ISP (-0,85 %)
$AMZN (+0,34 %)
$GOOG (+0,47 %)
$AMD (-0,56 %)
$NU (+0,5 %)

From 2020 to today, $OSCR grew revenues from ~$0.5B to nearly $3B per quarter — more than 6x in 5 years.

The growth story is clear. The real challenge now is reducing the Medical Loss Ratio and reaching profitability in 2026.

Today is $NBIS (+0 %) day

But great month for $OSCR and $UNH (-0,27 %)

Chinese Stock $BIDU (+9,1 %) and $BABA (+2,63 %)

We are in the last months of a bull market?

$OSCR

The health insurance sector has been crushed in 2025. UnitedHealth, Centene, Molina – all down ~40%. Wall Street calls it an “uninvestable sector.”

But Oscar looks different:

• 2M+ members (+28% YoY)
• Q2 revenue: $2.86B (+29% YoY, run-rate ~$11.8B)
• $2.6B cash vs only $0.3B debt
• EV/Sales = 0.1x while peers trade 0.4–0.6x

Yes, Medical Loss Ratio spiked to 91% and 2025 is a “reset year.” But management guides for profitability in 2026, and the GPT-5 Superagent makes Oscar look like a healthtech platform, not a traditional insurer.

📌 Street consensus: $10–12.

📌 My fair value: $25–34.

🚨 $OSCR reaffirms FY2025 revenue guidance at $12.0–$12.2B vs Street est. $11.32B at the Wells Fargo Conference.

Not just holding the line — guiding above consensus while the sector is still under pressure.

$OSCR confirmed at the Wells Fargo Healthcare Conference that its 2025 guidance remains unchanged.

No surprises, just a clear reaffirmation of the outlook shared in July. Sometimes, holding the line is all the market needs to hear.

$OSCR trades at just 0.1x EV/Sales, priced like it's near bankruptcy, despite $2.6B cash, 2M+ members, and a clear path to profitability in 2026. Fair value estimated at $25–34 vs $16 today, implying +55% to +110% upside if targets are met